Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.69M Hold
66,800
1.09% 27
2025
Q4
$3.28M Buy
+66,800
New +$3.12M 0.95% 25
2022
Q4
Sell
-218,200
Closed -$6.42M 99
2022
Q3
$6.42M Buy
218,200
+2,600
+1% +$98.5K 2.97% 16
2022
Q2
$11.7M Hold
215,600
4.13% 5
2022
Q1
$11.7M Hold
215,600
3.65% 7
2021
Q4
$11.9M Hold
215,600
3.82% 8
2021
Q3
$10.3M Buy
+215,600
New +$10.8M 3.45% 8

Other funds holding GSK

NKCFO LLC's GSK Position: Q1 2026 in Review

NKCFO LLC held its GSK (GSK) position steady in Q1 2026 at 66,800 shares worth $3.69M. The position accounts for 1.09% of the portfolio, ranked #27.

NKCFO LLC first reported a position in GSK in Q3 2021 and has held it in 7 quarters since. The position peaked at $11.9M in Q4 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • NKCFO LLC held 66,800 shares of GSK worth $3.69M as of Q1 2026.
  • NKCFO LLC left its GSK share count unchanged in Q1 2026.
  • GSK made up 1.09% of NKCFO LLC's portfolio in Q1 2026, its #27 holding.
  • NKCFO LLC first reported a position in GSK in Q3 2021 and has held it in 7 quarters since.
  • NKCFO LLC's GSK position peaked at $11.9M in Q4 2021.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on NKCFO LLC's 13F filing for Q1 2026, filed 11 May 2026.